Minimally Invasive Procedure Shows Promise for Osteoarthritis Relief Without Knee Replacement

A New Treatment Targets Root Cause of Knee Pain

A minimally invasive procedure called genicular artery embolization (GAE) is emerging as a potential alternative to knee replacement surgery for people with severe osteoarthritis. Instead of replacing damaged joints, the technique uses a thin catheter to deliver microscopic particles into specific blood vessels around the knee. These gelatin-based particles dissolve within hours and work by reducing blood flow to abnormal vessels that form around inflamed joints. Researchers hypothesize that by decreasing abnormal blood vessel growth and inflammation, the procedure may interrupt the cascade of pain signals and joint degradation associated with osteoarthritis.

Osteoarthritis affects more than 365 million adults worldwide and remains the most common form of arthritis, according to the World Health Organization. The condition involves progressive cartilage deterioration, chronic inflammation, and heightened pain nerve sensitivity. Standard treatments—physical therapy, anti-inflammatory medications, and joint injections—eventually lose effectiveness for many patients. At that point, knee replacement surgery becomes the typical option, but many patients cannot undergo surgery due to medical contraindications or personal preference. This creates what researchers describe as a significant treatment gap for millions of people.

Study Results Show Sustained Pain Relief Over One Year

Researchers conducted a prospective single-center trial involving 194 patients (114 women, 80 men, median age 69) with severe knee osteoarthritis who had failed conventional treatments for at least three months. The team performed 239 total GAE procedures between July and November 2024, with 45 patients receiving bilateral treatments for both knees. All procedures were technically successful, with no moderate or severe complications reported. Only 6.7% of procedures resulted in mild, temporary adverse events such as brief skin discoloration, all of which resolved without lasting effects.

Pain reduction was dramatic and persistent. Using a 0-to-10 pain scale, median pain scores dropped from 7 before treatment to 4 at six weeks, then declined further to 3 at six months and remained at that level through 12-month follow-up. This represents a reduction of more than 50% from baseline pain levels. Critically, 80% of patients who completed the 12-month assessment achieved clinically meaningful pain improvement—defined as at least a 2-point reduction on the pain scale. This threshold distinguishes changes noticeable in daily life from minor statistical improvements.

Functional Improvements Extend Beyond Pain Relief

The benefits extended significantly into daily activities and quality of life. Using standardized outcome measures, researchers found that patients reported improved ability to perform routine movements. Scores for daily activities (walking, climbing stairs) increased from 53 to 71.5 on their assessment scale. More importantly, sports and recreation scores nearly tripled, rising from 15 to 36, indicating patients could engage in more physically demanding activities. Osteoarthritis symptom scores climbed from 51 to 68, while pain-specific category scores improved from 44 to 65 on a scale where 100 represents complete pain freedom. Overall quality-of-life scores more than doubled, increasing from 19 to 40.

Follow-up compliance remained relatively high throughout the year, with 79% of enrolled patients providing 12-month data. The consistency of benefits across multiple assessment categories suggests the procedure's effects address multiple dimensions of osteoarthritis burden rather than providing isolated pain relief.

Unanswered Questions About Long-Term Effects

While the one-year results are encouraging, important questions remain about whether GAE can actually slow osteoarthritis progression or reverse existing damage. The study demonstrates that the procedure reduces inflammation and pain, but researchers did not measure whether it prevents cartilage deterioration or alters the underlying disease trajectory. The mechanism likely involves interrupting abnormal neurovascular interactions—the pathological relationship between excess blood vessels and pain-signaling nerves around the joint—rather than repairing damaged cartilage.

Researchers selected rapidly resorbable gelatin-based microspheres for this study specifically because they combine potential advantages of both temporary and permanent blocking agents. Previous investigations used either temporary blocking particles (which clear quickly but may be harder to deliver precisely) or permanent microspheres (more controlled delivery but permanent effects). These new particles offer controlled, targeted delivery to specific genicular arteries while dissolving within hours, potentially reducing long-term foreign body presence in blood vessels. The procedure qualifies as superselective embolization because doctors target individual small arteries rather than blocking circulation throughout the entire joint, preserving normal blood flow while interrupting abnormal vessel networks.